Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US90400D1081
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG001RWPDW6
RARE

Ultragenyx Pharmaceutical Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Ultragenyx Pharmaceutical Inc
ISIN
US90400D1081
TICKER
RARE
MIC
XNAS
REUTERS
RARE.OQ
BLOOMBERG
RARE US
Sat, 21.03.2026       Ultragenyx Pharmaceutical

NEW ORLEANS, March 20, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE), if they purchased or otherwise acquir...
Ultragenyx Pharmaceutical
Fri, 20.03.2026       Ultragenyx Pharmaceutical

NOVATO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 10,839 restricted stock units of the company’s common stock to two newly hired non-executive...
Ultragenyx Pharmaceutical
Fri, 20.03.2026       Ultragenyx Pharmaceutical

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Ultragenyx Pharmaceutical
Fri, 20.03.2026       Ultragenyx Pharmaceutical

NEW YORK, March 19, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusi...
Ultragenyx Pharmaceutical
Thu, 19.03.2026       Ultragenyx Pharmaceutical

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire...
Ultragenyx Pharmaceutical
Thu, 19.03.2026       Ultragenyx Pharmaceutical

SAN DIEGO, March 19, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, all dates inclusive (the "Class Period"), have until Monday, April 6, 2026 to seek appointment as lead plaintiff of the Ultragen...
Ultragenyx Pharmaceutical
Wed, 18.03.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Ultragenyx Pharmaceutical
Wed, 18.03.2026       Ultragenyx Pharmaceutical

Know Your Rights: How Basic Inc. v. Levinson Enables Investor RecoveryNEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)....
Ultragenyx Pharmaceutical
Tue, 17.03.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - March 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Ultragenyx Pharmaceutical
Tue, 17.03.2026       Ultragenyx Pharmaceutical

NEW YORK, March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are enc...
Ultragenyx Pharmaceutical
Silent Ad
Mon, 16.03.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - March 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purc...
Ultragenyx Pharmaceutical
Mon, 16.03.2026       Ultragenyx Pharmaceutical

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Ultragenyx Pharmaceutical
Mon, 16.03.2026       Ultragenyx Pharmaceutical

Philadelphia, Pennsylvania--(Newsfile Corp. - March 16, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2023...
Ultragenyx Pharmaceutical
Sun, 15.03.2026       Ultragenyx Pharmaceutical

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Ultragenyx Pharmaceutical
Sat, 14.03.2026       Ultragenyx Pharmaceutical

NEW YORK and NEW ORLEANS, March 13, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE) of a class action securities lawsuit.   CLASS DEFINI...
Ultragenyx Pharmaceutical
Fri, 13.03.2026       Ultragenyx Pharmaceutical

SAN DIEGO, March 13, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), have until Monday, April 6, 2026 to seek appointment as lead plaintiff of the Ul...
Ultragenyx Pharmaceutical
Fri, 13.03.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - March 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purc...
Ultragenyx Pharmaceutical
Thu, 12.03.2026       Ultragenyx Pharmaceutical

NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire...
Ultragenyx Pharmaceutical
Thu, 12.03.2026       Ultragenyx Pharmaceutical

LOS ANGELES, March 12, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated there...
Ultragenyx Pharmaceutical
Thu, 12.03.2026       Ultragenyx Pharmaceutical

LOS ANGELES, March 12, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissi...
Ultragenyx Pharmaceutical
Silent Ad
Thu, 12.03.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - March 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purc...
Ultragenyx Pharmaceutical
Wed, 11.03.2026       Ultragenyx Pharmaceutical

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Ultragenyx Pharmaceutical
Wed, 11.03.2026       Ultragenyx Pharmaceutical

Important Information Regarding Section 20(a) Individual Liability ClaimsRARE INVESTOR ALERTNEW YORK, March 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) of a pending securities class action. To be considered for lead plaintiff, investors must file by April 6, 2026....
Ultragenyx Pharmaceutical
Tue, 10.03.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - March 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purc...
Ultragenyx Pharmaceutical
Tue, 10.03.2026       Ultragenyx Pharmaceutical

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Ultragenyx Pharmaceutical
Tue, 10.03.2026       Ultragenyx Pharmaceutical

NEW YORK, March 10, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are enc...
Ultragenyx Pharmaceutical
Mon, 09.03.2026       Ultragenyx Pharmaceutical

NEW YORK, March 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusiv...
Ultragenyx Pharmaceutical
Mon, 09.03.2026       Ultragenyx Pharmaceutical

Philadelphia, Pennsylvania--(Newsfile Corp. - March 9, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2023...
Ultragenyx Pharmaceutical
Mon, 09.03.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - March 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purch...
Ultragenyx Pharmaceutical
Sun, 08.03.2026       Ultragenyx Pharmaceutical

Did you buy RARE common stock between August 3, 2023, and December 26, 2025?Affected Ultragenyx Pharmaceutical Inc. Investor SummaryWho: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)What: Securities fraud class action lawsuit filedClass Period: August 3, 2023, through December 26, 2025Deadline to Seek Lead Plaintiff Status: April 6, 2026Key Lawsui...
Ultragenyx Pharmaceutical
Sun, 08.03.2026       Ultragenyx Pharmaceutical

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Ultragenyx Pharmaceutical
Sun, 08.03.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - March 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purch...
Ultragenyx Pharmaceutical
Sat, 07.03.2026       Ultragenyx Pharmaceutical

NEW ORLEANS, March 6, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE), if they purchased or otherwise acquire...
Ultragenyx Pharmaceutical
Sat, 07.03.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - March 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purch...
Ultragenyx Pharmaceutical
Fri, 06.03.2026       Ultragenyx Pharmaceutical

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Ultragenyx Pharmaceutical
Fri, 06.03.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - March 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Ultragenyx Pharmaceutical
Thu, 05.03.2026       Ultragenyx Pharmaceutical

NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire b...
Ultragenyx Pharmaceutical
Thu, 05.03.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - March 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purch...
Ultragenyx Pharmaceutical
Wed, 04.03.2026       Ultragenyx Pharmaceutical

SAN DIEGO, March 4, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, both dates inclusive (the "Class Period"), have until Monday, April 6, 2026 to seek appointment as lead plaintiff of the Ultragen...
Ultragenyx Pharmaceutical
Wed, 04.03.2026       Ultragenyx Pharmaceutical

Alert: Claims Focus on Alleged Misrepresentations About Setrusumab Efficacy PotentialNEW YORK, March 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) securities of a pending securities class action. Investors have until April 6, 2026 to seek lead plaintiff status....
Ultragenyx Pharmaceutical
Tue, 03.03.2026       Ultragenyx Pharmaceutical

NEW YORK, March 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusiv...
Ultragenyx Pharmaceutical
Tue, 03.03.2026       Ultragenyx Pharmaceutical

NEW YORK, March 3, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are enco...
Ultragenyx Pharmaceutical
Tue, 03.03.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - March 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Ultragenyx Pharmaceutical
Mon, 02.03.2026       Ultragenyx Pharmaceutical

Did you buy RARE common stock between August 3, 2023, and December 26, 2025?Affected Ultragenyx Pharmaceutical Inc. Investor SummaryWho: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)What: Securities fraud class action lawsuit filedClass Period: August 3, 2023, through December 26, 2025Deadline to Seek Lead Plaintiff Status: April 6, 2026Key Lawsui...
Ultragenyx Pharmaceutical
Mon, 02.03.2026       Ultragenyx Pharmaceutical

LOS ANGELES, March 2, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereu...
Ultragenyx Pharmaceutical
Mon, 02.03.2026       Ultragenyx Pharmaceutical

LOS ANGELES, March 2, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commis...
Ultragenyx Pharmaceutical
Sun, 01.03.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - March 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Ultragenyx Pharmaceutical
Sat, 28.02.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - February 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If...
Ultragenyx Pharmaceutical
Sat, 28.02.2026       Ultragenyx Pharmaceutical

NEW YORK and NEW ORLEANS, Feb. 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE) of a class action securities lawsuit.   CLASS DEFINIT...
Ultragenyx Pharmaceutical
Fri, 27.02.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - February 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If...
Ultragenyx Pharmaceutical